Innovations extend across diagnostic and therapeutic devices. Heartflow received FDA clearance for its next-generation plaque analysis algorithm demonstrating 21% improved detection over previous versions, with insurance coverage starting October. A novel dual-camera system has improved lower-limb kinematic analysis in osteoarthritis patients, enhancing clinical diagnostics. Cyclerion announced its strategic transformation to focus on neuropsychiatric disorders, harnessing licensed technology targeting treatment-resistant depression with a phase 2 trial planned for 2026.